# Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs

> **NCT00634985** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 120 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** eletriptan

## Key facts

- **NCT ID:** NCT00634985
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2003-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634985, "Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00634985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*